Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance and Mylan Biosimilar to BOTOX® Program Decision to Extend Beyond April 30, 2020

Business Wire May 1, 2020

Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020

Business Wire April 30, 2020

Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors

GlobeNewswire April 21, 2020

Revance to Participate in the 19th Annual Needham Virtual Healthcare Conference

Business Wire April 7, 2020

Revance Provides Corporate Update in Light of COVID-19

Business Wire March 26, 2020

Revance to Participate in the Barclays Global Healthcare Conference 2020

Business Wire March 3, 2020

Revance to Participate in the Cowen 40th Annual Health Care Conference

Business Wire February 25, 2020

Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update

Business Wire February 24, 2020

Revance to Release Fourth Quarter and Full Year 2019 Financial Results on Monday, February 24, 2020

Business Wire February 14, 2020

Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027

Business Wire February 12, 2020

Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027

Business Wire February 10, 2020

Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines

Business Wire February 6, 2020

Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA

Business Wire January 10, 2020

Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference

Business Wire January 9, 2020

Revance Provides Corporate Update and Anticipated Milestones for 2020

Business Wire January 9, 2020

Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

Business Wire December 5, 2019

Revance Announces Pricing of Public Offering of Common Stock

Business Wire December 4, 2019

Revance Announces Proposed Public Offering of Common Stock

Business Wire December 3, 2019

Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics

Business Wire December 2, 2019

Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines

Business Wire November 25, 2019